April 23, 2021
Article
The Cancer Support Community's Biomarker Testing Tool can help identify which targeted therapy should be used for treatment in patients with lung cancer.
FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer
Lunsumio plus Polivy Associated With Responses in MCL
Standing Up to Cancer with Lynch Syndrome
Zidesamtinib Elicits Responses in ROS1-Positive NSCLC